Clinical reference Biomarker Directory
Back to directory

Carbohydrate Antigen 125

Established

CA-125 is the standard blood test for ovarian cancer monitoring, though not specific enough for standalone diagnosis.

Also known as CA-125 cancer antigen 125 MUC16
In plain language

CA-125 is the classic ovarian cancer blood test, but it also rises with several harmless conditions, so it isn't used alone to diagnose cancer. It's most useful for tracking how well treatment is working over time, alongside imaging.

Biomarker & context

CA-125 is a glycoprotein antigen expressed on the surface of ovarian epithelial cells and other tissues, serving as the longstanding standard-of-care biomarker for ovarian cancer surveillance and treatment monitoring.

What it indicates

Elevated CA-125 is associated with ovarian cancer but also with benign conditions (endometriosis, menstruation, pelvic inflammatory disease, pregnancy), giving it real limited specificity for diagnosis alone, especially in premenopausal women.

Diagnosis & clinical testing

Current guideline consensus (ESGO 2024/2025, NCCN 2025) states CA-125, with or without HE4, should not be used alone to distinguish benign from malignant ovarian tumors, and general population screening is not recommended since it doesn't reduce cancer deaths. The CA-125 elimination rate constant (KELIM), calculated from serial levels over the first 100 days of treatment, provides prognostic information beyond a single reading.

Guiding treatment

Response criteria are standardized by the Gynecological Cancer Intergroup (GCIG), with a confirmatory test required at least 28 days after an initial response is documented. Studies comparing CA-125 against imaging have found real discordance — CA-125 can signal progression months before imaging confirms it, a double-edged early-warning/premature-change-of-therapy risk.

Clinical significance

Best used for treatment response and recurrence monitoring, not as a standalone screening or diagnostic test.

References
  1. ESGO. (2025). Pocket Guidelines: Ovarian Cancer Consensus.
  2. J. Cancer. Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer.